Charles Schwab Investment Management Inc Protagonist Therapeutics, Inc Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 575,364 shares of PTGX stock, worth $31.4 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
575,364
Previous 557,718
3.16%
Holding current value
$31.4 Million
Previous $27 Million
17.9%
% of portfolio
0.01%
Previous 0.01%
Shares
29 transactions
Others Institutions Holding PTGX
# of Institutions
302Shares Held
67.5MCall Options Held
371KPut Options Held
360K-
Farallon Capital Management LLC San Francisco, CA6.17MShares$337 Million1.53% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$314 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.76MShares$314 Million4.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.36MShares$238 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.25MShares$177 Million6.36% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.68B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...